Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein GraftsResults From the Randomized DELAYED RRISC Trial
Paul Vermeersch, MD,
Pierfrancesco Agostoni, MD*,
Stefan Verheye, MD, PhD,
Paul Van den Heuvel, MD,
Carl Convens, MD,
Frank Van den Branden, MD,
Glenn Van Langenhove, MD, PhD for the DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators
Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp, Belgium
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Survival Curves
Kaplan-Meier estimates for survival by type of randomized stent (dotted blue line = bare-metal stent [BMS]; continuous red line = sirolimus-eluting stent [SES]).
|
|
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 TVR-Free Survival Curves
Kaplan-Meier estimates for target vessel revascularization (TVR)-free survival by type of randomized stent (dotted blue line = BMS; continuous red line = SES). Abbreviations as in Figure 1.
|
|
|
